Related references
Note: Only part of the references are listed.Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial
Eiichi Araki et al.
DIABETES OBESITY & METABOLISM (2020)
Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial
Chantal Mathieu et al.
DIABETES OBESITY & METABOLISM (2020)
Japanese Clinical Practice Guideline for Diabetes 2019
Eiichi Araki et al.
JOURNAL OF DIABETES INVESTIGATION (2020)
Japanese Clinical Practice Guideline for Diabetes 2019
Eiichi Araki et al.
DIABETOLOGY INTERNATIONAL (2020)
International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors
Thomas Danne et al.
DIABETES CARE (2019)
Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus
Victor Sokolov et al.
DIABETES OBESITY & METABOLISM (2019)
SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A South Australian Clinical Case Series and Australian Spontaneous Adverse Event Notifications
Emily J. Meyer et al.
DIABETES CARE (2018)
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial
Chantal Mathieu et al.
DIABETES CARE (2018)
Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial
Akira Shimada et al.
DIABETES OBESITY & METABOLISM (2018)
Japanese Clinical Practice Guideline for Diabetes 2016
Masakazu Haneda et al.
JOURNAL OF DIABETES INVESTIGATION (2018)
Body mass index ≥23 is a risk factor for insulin resistance and diabetes in Japanese people: A brief report
Tsuyoshi Okura et al.
PLOS ONE (2018)
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study
Paresh Dandona et al.
DIABETES CARE (2018)
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
Paresh Dandona et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
Gian Paolo Fadini et al.
DIABETOLOGIA (2017)
Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study
Robert R. Henry et al.
DIABETES OBESITY & METABOLISM (2017)
SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis
Ronald M. Goldenberg et al.
CLINICAL THERAPEUTICS (2016)
Type 1 diabetes prevalence increasing globally and regionally: the role of natural selection and life expectancy at birth
Wen-Peng You et al.
BMJ OPEN DIABETES RESEARCH & CARE (2016)
Current State of Type 1 Diabetes Treatment in the US: Updated Data From the T1D Exchange Clinic Registry
Kellee M. Miller et al.
DIABETES CARE (2015)
The Effect of Hypoglycemia on Health-Related Quality of Life: Canadian Results from a Multinational Time Trade-off Survey
Stewart Harris et al.
CANADIAN JOURNAL OF DIABETES (2014)
Body Composition Is the Main Determinant for the Difference in Type 2 Diabetes Pathophysiology Between Japanese and Caucasians
Jonas B. Moller et al.
DIABETES CARE (2014)
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years
J. P. H. Wilding et al.
DIABETES OBESITY & METABOLISM (2014)
Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events
Agata Ptaszynska et al.
DRUG SAFETY (2014)
The Effect of Excess Weight Gain With Intensive Diabetes Mellitus Treatment on Cardiovascular Disease Risk Factors and Atherosclerosis in Type 1 Diabetes Mellitus Results From the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) Study
Jonathan Q. Purnell et al.
CIRCULATION (2013)
Hypoglycemia and Cardiovascular Risks
Brian M. Frier et al.
DIABETES CARE (2011)
Biology of Human Sodium Glucose Transporters
Ernest M. Wright et al.
PHYSIOLOGICAL REVIEWS (2011)
Obesity and Cardiovascular Disease Risk Factor, Paradox, and Impact of Weight Loss
Carl J. Lavie et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes
E. S. Kilpatrick et al.
DIABETOLOGIA (2007)
Share Paper
